SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

RC298

VOR·Vor Biopharma Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Preclinical (IND-enabling)
Time to market
RC298 is in IND-enabling (preclinical) development. An IND submission in China is expected in H1 2027. If clinical development proceeds, an approved product would likely be several years away, assuming successful Phase 1, 2, and 3 trials.
Why 4/10
RC298 is a preclinical (IND-enabling) asset with no clinical trials yet; the next catalyst is an IND submission in China expected in H1 2027, roughly 6-8 months away, but this is a non-binary regulatory step for a pipeline-expansion asset that is not the company's primary value driver (telitacicept is). The deal was already announced and priced in on Nov 12, 2026.
Actionable Insight NEUTRAL

Watch for the IND submission for RC298 in China expected H1 2027. Near-term stock movement will likely come from telitacicept Phase 3 readouts (UPSTREAM MG and SjD topline data expected 1H 2027), not RC298. The deal's upfront cost ($10M cash + ~$46M in warrants) and potential future dilution from the $150M ATM facility create an overhang to monitor.

Price Chart

Loading chart...

Executive Summary

RC298 is a preclinical, next-generation, long-acting dual BAFF/APRIL inhibitor that Vor Biopharma licensed from RemeGen on November 12, 2026, for ex-Greater China rights. Vor Bio paid $10M in cash plus a pre-funded warrant for 2.3M shares (valued at ~$46M) upfront, with up to $300M in potential development milestones. The drug is in IND-enabling development, with an IND submission in China expected in H1 2027. RC298 is a pipeline-expansion asset; Vor Bio's primary value driver is telitacicept (a first-generation BAFF/APRIL inhibitor in Phase 3 for multiple autoimmune indications). For a non-medical investor, RC298 is an early-stage speculative addition to an existing franchise, not a near-term binary catalyst. Vor Biopharma (VOR) trades on Nasdaq at ~$19.42 with a market cap of roughly $1.23B, carries a Strong Buy analyst consensus (mean target $39), and has cash runway into early 2029.

How It Works

RC298 is a dual BAFF/APRIL inhibitor, meaning it blocks two immune-signaling proteins (BAFF and APRIL) that are overactive in autoimmune diseases. By neutralizing both targets, the drug aims to reduce the production of self-attacking antibodies while sparing broader immune function. RC298 is designed as a long-acting, next-generation version with higher potency and a longer half-life, which could mean less frequent dosing than the first-generation drug telitacicept.

Trial Status

RC298 has not yet entered clinical trials. It is in IND-enabling development, with the company targeting an IND submission in China in the first half of 2027. Preclinical data on potency and half-life were cited as encouraging by the company but have not been publicly disclosed in detail.

The Two-Sided Case

▲ Bull Case4
RC298 is a next-generation, long-acting dual BAFF/APRIL inhibitor designed for higher potency and extended half-life, offering potential best-in-class dosing convenience over first-generation telitacicept in a validated autoimmune mechanism.
The deal expands Vor Bio's BAFF/APRIL franchise (already anchored by telitacicept's positive Phase 3 data in IgA nephropathy and myasthenia gravis), creating a potential pipeline-in-a-product strategy.
Vor Bio secured exclusive rights to RC298 outside Greater China at a relatively modest upfront ($56M total), with the existing milestone/royalty framework from the original telitacicept deal already in place, suggesting disciplined capital allocation.
Analyst consensus is Strong Buy (12 buy/strong buy vs 2 hold) with a mean price target of $39 (~100% implied upside), and major institutional holders (Fidelity, BlackRock, Vanguard) added or increased positions in Q3 2026.
▼ Bear Case5
RC298 is in IND-enabling (preclinical) development with no clinical data yet; clinical failure or delays are the primary risk. The program may never reach human studies.
The upfront cost to Vor Bio is significant: $10M cash plus a pre-funded warrant for 2.3 million shares at $0.0001/share (valued at ~$46M based on the Nov 11 closing price), creating immediate shareholder dilution.
Up to $300M in additional development milestones plus royalties could burden Vor Bio's balance sheet if the program advances, straining its cash runway (though currently into early 2029).
Vor Bio relies on RemeGen for preclinical and Phase 1 development in China; data from Chinese studies may not be accepted by FDA or EMA for global registration.
The existing $150M ATM equity facility adds further potential dilution, and RC298 is a speculative early-stage asset within a company already burning significant cash (Q3 2026 net loss ~$86.7M).

Upcoming Catalysts

  • IND submission for RC298 in China expected H1 2027
  • Telitacicept Phase 3 UPSTREAM MG (myasthenia gravis) topline data expected 1H 2027 (separate asset but same franchise and company)
  • Telitacicept Phase 3 UPSTREAM SjD (Sjögren's disease) topline data expected 1H 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vor Biopharma Inc. 8-K VOR ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 fiercebiotech.com3 seekingalpha.com